Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Concerning the Monthly Exercise Status of the 58th and 66th Series Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions)

In August 2026, there were no exercises of the 58th or 66th stock acquisition rights, and 0 shares were delivered. The remaining 58th and 66th stock acquisition rights have been acquired and are scheduled to be cancelled in full on 1 September 2026.

Worth reading
30Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
Shares
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Monthly report on the exercise status of stock acquisition rights with exercise price adjustment provisions issued through a third-party allotment

発行・処分する株式数

Shares delivered during the month: 0 shares (0 newly issued shares and 0 treasury shares transferred)

Intended allottee
Name EVO FUND / Subject Series 66 stock acquisition rights / Number of Shares Not disclosed, Name CVI Investments,Inc. / Subject Series 58 stock acquisition rights / Number of Shares Not disclosed
発行済株式総数

Exercise ratio for the relevant month: 0%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price during the relevant month was ¥84 for both the 66th and 58th stock acquisition rights. Details of the exercise price adjustment provisions and the adjustment floor: not disclosed
Number of Stock Acquisition Rights
66th: total issued, 200,000 rights; unexercised at the end of the relevant month, 120,510 rights. 58th: total issued, 20,000 rights; unexercised at the end of the relevant month, 20,000 rights
Reason for acquisition without consideration
The 58th stock acquisition rights remaining as of 17 August 2026 were acquired without consideration as of 18 August 2026, and the 66th and 67th stock acquisition rights remaining as of the date hereof were acquired without consideration as of the date hereof
Most recent equity financing
Timing 12 August 2025 / Type Issuance of the 65th through 67th stock acquisition rights / Amount Not disclosed, Timing 1 June 2022 / Type Issuance of Series 58 stock acquisition rights / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly report on the exercise status of stock acquisition rights with exercise price adjustment provisions issued through a third-party allotment
Number of shares to be issued or disposed ofShares delivered during the month: 0 shares (0 newly issued shares and 0 treasury shares transferred)
Intended allotteeName EVO FUND / Subject Series 66 stock acquisition rights / Number of Shares Not disclosed, Name CVI Investments,Inc. / Subject Series 58 stock acquisition rights / Number of Shares Not disclosed
Dilution RateExercise ratio for the relevant month: 0%
Total number of issued shares80,246,460 shares (including 91,244 treasury shares) → 80,246,460 shares (including 91,244 treasury shares)(0%)
Exercise priceThe exercise price during the relevant month was ¥84 for both the 66th and 58th stock acquisition rights. Details of the exercise price adjustment provisions and the adjustment floor: not disclosed
Number of Stock Acquisition Rights66th: total issued, 200,000 rights; unexercised at the end of the relevant month, 120,510 rights. 58th: total issued, 20,000 rights; unexercised at the end of the relevant month, 20,000 rights
Reason for acquisition without considerationThe 58th stock acquisition rights remaining as of 17 August 2026 were acquired without consideration as of 18 August 2026, and the 66th and 67th stock acquisition rights remaining as of the date hereof were acquired without consideration as of the date hereof
Most recent equity financingTiming 12 August 2025 / Type Issuance of the 65th through 67th stock acquisition rights / Amount Not disclosed, Timing 1 June 2022 / Type Issuance of Series 58 stock acquisition rights / Amount Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The 58th stock acquisition rights are deemed to constitute “MSCB, etc.” in connection with the issuance of the 65th through 67th stock acquisition rights, making disclosure of their monthly exercise status necessary. Disclosure of the monthly exercise status of the 67th stock acquisition rights has been omitted because, under the purchase agreement, they are structured so that, in principle, they cannot be exercised until 13 August 2027.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 58th and 66th Series Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions) | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori